Makoto Chuma, Haruki Uojima, Atsushi Hiraoka, Satoshi Kobayashi, Hidenori Toyoda, Toshifumi Tada, Hisashi Hidaka, Shogo Iwabuchi, Kazushi Numata, Ei Itobayashi, Norio Itokawa, Kazuya Kariyama, Hideko Ohama, Nobuhiro Hattori, Shunji Hirose, Hiroshi Shibata, Joji Tani, Michitaka Imai, Kazuto Tajiri, Satoshi Moriya, Naohisa Wada, Shuitirou Iwasaki, Taito Fukushima, Makoto Ueno, Satoshi Yasuda, Masanori Atsukawa, Kazuhiro Nouso, Shinya Fukunishi, Tsunamasa Watanabe, Toru Ishikawa, Shinichiro Nakamura, Manabu Morimoto, Tatehiro Kagawa, Michiie Sakamoto, Takashi Kumada, Shin Maeda,
Aims To assess the safety, efficacy, and prognostic impact of clinical factors associated with lenvatinib treatment in highly advanced hepatocellular carcinoma (HCC) with tumor thrombus in the main portal vein trunk (VP4) or tumor with more than 50% liver occupation (tm50%LO). Methods A total of 61 highly advanced HCC patients (41 patients with tm50%LO and 20 patients with VP4) who were treated with lenvatinib at multicenter were enrolled and retrospectively analyzed for treatment outcomes according ...
Tópico(s): Hepatitis B Virus Studies
2020 - Wiley | Hepatology Research
Tatsuro Tajiri, Satoshi Ieiri, Yoshiaki Kinoshita, Kouji Masumoto, Yuko Nishimoto, Tomoaki Taguchi,
Tópico(s): Congenital gastrointestinal and neural anomalies
2008 - Springer Science+Business Media | Pediatric Surgery International
Yoshiaki Kinoshita, Tatsuro Tajiri, Satoshi Ieiri, Kyoko Nagata, Tomoaki Taguchi, Sachiyo Suita, Koji Yamazaki, Ichiro Yoshino, Yoshihiko Maehara, Kenichi Kohashi, Hidetaka Yamamoto, Yoshinao Oda, Masazumi Tsuneyoshi,
Tópico(s): Histiocytic Disorders and Treatments
2006 - Springer Science+Business Media | Pediatric Surgery International
Yoshihiro Kanemitsu, Kensuke Fukumitsu, Ryota Kurokawa, Norihisa Takeda, Motohiko Suzuki, Jennifer Maries Yap, Hirono Nishiyama, Tomoko Tajiri, Satoshi Fukuda, Takehiro Uemura, Hirotsugu Ohkubo, Ken Maeno, Yutaka Ito, Tetsuya Oguri, Masaya Takemura, Akio Niimi,
Rationale: Capsaicin cough reflex sensitivity (C-CS) is associated with poorly controlled asthma, although its association with severe asthma remains unknown.Objectives: To determine the clinical impact of C-CS on severe asthma.Methods: We prospectively enrolled 157 patients with asthma (including 122 patients with severe asthma who were in step 4 or 5 according to the Global Initiative for Asthma 2015 guidelines) between November 2016 and October 2019. A capsaicin cough challenge was performed along ...
Tópico(s): Allergic Rhinitis and Sensitization
2020 - American Thoracic Society | American Journal of Respiratory and Critical Care Medicine
Eiso Hiyama, Tomoro Hishiki, Kenichiro Watanabe, Kohmei Ida, Yuka Ueda, Sho Kurihara, Michihiro Yano, Ken Hoshino, Akiko Yokoi, Yuichi Takama, Yuki Nogami, Tomoaki Taguchi, Makiko Mori, Kentaro Kihira, Osamu Miyazaki, Hiroshi Fuji, Shohei Honda, Tomoko Iehara, Takuro Kazama, Junya Fujimura, Yukichi Tanaka, Takeshi Inoue, Tatsuro Tajiri, Satoshi Kondo, Takaharu Oue, Kenichi Yoshimura,
We report here the outcomes and late effects of the Japanese Study Group for Pediatric Liver Tumors (JPLT)-2 protocol, on the basis of cisplatin-tetrahydropyranyl-adriamycin (CITA) with risk stratification according to the pretreatment extent of disease (PRETEXT) classification for hepatoblastoma (HB).From 1999 to 2012, 361 patients with untreated HB were enrolled. PRETEXT I/II patients were treated with up-front resection, followed by low-dose CITA (stratum 1) or received low-dose CITA, followed by ...
Tópico(s): Acute Lymphoblastic Leukemia research
2020 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
... storytelling in youth media today. Based around creator Satoshi Tajiri’s love of insect collecting, Pokémon imagines a ...
Tópico(s): Media Influence and Health
2013 - SAGE Publishing | International Journal of Cultural Studies
Kazuko Tajiri, Satoshi Sakai, Taizo Kimura, Tomoko Machino‐Ohtsuka, Nobuyuki Murakoshi, Dongzhu Xu, Zheng Wang, Akira Sato, Takashi Miyauchi, Kazutaka Aonuma,
Myocarditis and subsequent dilated cardiomyopathy are major causes of heart failure in young adults. Experimental autoimmune myocarditis (EAM) is a mouse model of post-infectious myocarditis and inflammatory cardiomyopathy. The pathological role of endothelin (ET) in myocarditis has not been elucidated.EAM was induced by immunization of cardiac myosin peptide with complete Freund's adjuvant on days 0 and 7 in BALB/c mice. An ETA/ETB dual receptor antagonist, SB209670, was administered by a continuous ...
Tópico(s): Eosinophilic Disorders and Syndromes
2014 - Elsevier BV | Life Sciences
Hsuan Chung, Satoshi Tajiri, Mai Hyoguchi, Riho Koyanagi, Akihiro Shimura, Fuyuko Takata, Shinya Dohgu, Toshiro Matsui,
In this study, a simultaneous assay for catecholamines and their metabolites in the brain was established using liquid chromatography-mass spectrometry (LC-MS). To achieve complete separation, a cation-exchange/reversed-phase mixed-mode copolymer resin column containing 0.81 wt% sulfo groups was used for the simultaneous LC-MS assay. The analyzed catecholamines were dopamine (DA), norepinephrine (NE), and epinephrine (E), while the metabolites lacking amino groups were 3,4-dihydroxyphenylacetic acid ( ...
Tópico(s): Electrochemical sensors and biosensors
2018 - Springer Nature | Analytical Sciences
Satoshi Sakai, Nobutake Shimojo, Taizo Kimura, Kazuko Tajiri, Hidekazu Maruyama, Satoshi Homma, Keisuke Kuga, Taro Mizutani, Kazutaka Aonuma, Takashi Miyauchi,
Cardiac hypertrophy is elicited by endothelin (ET)-1 as well as other neurohumoral factors, hemodynamic overload, and oxidative stress; HMG-CoA reductase inhibitors (statins) were shown to inhibit cardiac hypertrophy partly via the anti-oxidative stress. One of their common intracellular pathways is the phosphorylation cascade of MEK signaling. Pin1 specifically isomerizes the phosphorylated protein with Ser/Thr-Pro bonds and regulates their activity through conformational changes. There is no report ...
Tópico(s): Toxin Mechanisms and Immunotoxins
2014 - Elsevier BV | Life Sciences
Ryota Katsumi, Yasutomo Ota, Takeyoshi Tajiri, Satoshi Iwamoto, Kaur Ranbir, Johann Peter Reithmaier, Mohamed Benyoucef, Yasuhiko Arakawa,
Abstract We report the hybrid integration of a telecom band InAs/InP quantum-dot (QD) single-photon source on a CMOS-processed Si photonics chip using transfer printing. The integration technique allows for the assembly of photonic components in a pick-and-place operation and therefore can introduce them on Si photonics chips after completing the entire CMOS-compatible fabrication processes. We demonstrate telecom single-photon generation from an InAs/InP QD integrated on Si and its coupling into ...
Tópico(s): Semiconductor Quantum Structures and Devices
2022 - Institute of Physics | Applied Physics Express
Suning Luo, Shigemi Kohiki, Koichi Okada, Atsushi Kohno, Takayuki Tajiri, M. Arai, Satoshi Ishii, Daiichiro Sekiba, Masanori Mitome, Fumiya Shoji,
X-ray photoelectron spectroscopy (XPS) and Rutherford backscattering spectroscopy−elastic recoil detection analysis (RBS−ERDA) revealed that hydrogen in working gas for dc-plasma sputter deposition resided in indium tin oxide (ITO) films and generated the O− state seen as the suboxide-like O 1s peak in XPS. Growth of the suboxide-like O 1s peak was parallel with an increase of the resided hydrogen quantified by RBS−ERDA. The first-principles band structure calculation revealed that the electronic structure ...
Tópico(s): Ga2O3 and related materials
2010 - American Chemical Society | ACS Applied Materials & Interfaces
Isao Sakaida, M. Yanase, Yoshio Kobayashi, T Yasutake, Mitsuru Okada, K Okita, Fujito Kageyama, Hiroaki Miyaoka, Hiroki Nakamura, Hiroshi Sakaeda, Kazuya Kariyama, Kenji Takaishi, Kouji Joukou, Makoto Nakamuta, Masahide Oshita, Masahiro Arai, Masaki Mita, Masaki Omoto, Mitsushige Shibatouge, Nobuyoshi Tajiri, Nobuyoshi Tanaka, Satoshi Mochida, Syotaro Sakisaka, Takafumi Ichida, Tetsuro Inokuma, Toshiaki Takayanagi, Toshiji Saibara, Toshiyuki Kimura, Tsukasa Aihara, Yoshio Tokumoto,
This study investigated the pharmacokinetic and pharmacodynamic profile of tolvaptan, and verified its efficacy and safety in patients with liver cirrhosis-associated ascites, with insufficient response to conventional diuretic treatment.This multicentre, double-blind, parallel-group study allocated patients with cirrhosis to receive either 3.75 or 7.5 mg/day tolvaptan orally, once daily, for 7 days. Pharmacokinetic, pharmacodynamic and efficacy variables were measured.Tolvaptan was shown to have ...
Tópico(s): Renal function and acid-base balance
2012 - SAGE Publishing | Journal of International Medical Research
Tomoko Machino‐Ohtsuka, Kazuko Tajiri, Taizo Kimura, Satoshi Sakai, Akira Sato, Toshimichi Yoshida, Michiaki Hiroe, Yasuhiro Yasutomi, Kazutaka Aonuma, Kyoko Imanaka‐Yoshida,
Background Tenascin‐C ( TN ‐C), an extracellular matrix glycoprotein, appears at several important steps of cardiac development in the embryo, but is sparse in the normal adult heart. TN ‐C re‐expresses under pathological conditions including myocarditis, and is closely associated with tissue injury and inflammation in both experimental and clinical settings. However, the pathophysiological role of TN ‐C in the development of myocarditis is not clear. We examined how TN ‐C affects the initiation of experimental ...
Tópico(s): Viral Infections and Immunology Research
2014 - Wiley | Journal of the American Heart Association
Rie Tajiri, Tatsuya Setoguchi, Satoshi Wakizono, Kazuya Yamamoto, Jun‐ichi Kadokawa,
Tópico(s): Advanced Cellulose Research Studies
2013 - American Scientific Publishers | Journal of Biobased Materials and Bioenergy
Kazuko Tajiri, Nobutake Shimojo, Satoshi Sakai, Tomoko Machino‐Ohtsuka, Kyoko Imanaka-Yoshida, Michiaki Hiroe, Yusuke Tsujimura, Taizo Kimura, Akira Sato, Yasuhiro Yasutomi, Kazutaka Aonuma,
Tópico(s): Systemic Lupus Erythematosus Research
2013 - Springer Science+Business Media | Cardiovascular Drugs and Therapy
S. Takahashi, Yasutomo Ota, Takeyoshi Tajiri, Jun Tatebayashi, Satoshi Iwamoto, Yasuhiko Arakawa,
The modification of a circularly polarized vacuum field in three-dimensional chiral photonic crystals was measured by spontaneous emission from quantum dots in the structures. Due to the circularly polarized eigenmodes along the helical axis in the GaAs-based mirror-asymmetric structures involved, the authors observed highly circularly-polarized emission from the quantum dots. Both spectroscopic and time-resolved measurements confirmed that the obtained circularly-polarized light was influenced ...
Tópico(s): Plasmonic and Surface Plasmon Research
2017 - American Physical Society | Physical review. B./Physical review. B
Taizo Kimura, Kazuko Tajiri, Akira Sato, Satoshi Sakai, Zheng Wang, Toshimichi Yoshida, Toshimitsu Uede, Michiaki Hiroe, Kazutaka Aonuma, Masaki Ieda, Kyoko Imanaka‐Yoshida,
Abstract Aims Tenascin-C (TN-C) is an extracellular matrix protein undetected in the normal adult heart, but expressed in several heart diseases associated with inflammation. We previously reported that serum TN-C levels of myocardial infarction (MI) patients were elevated during the acute stage, and that patients with high peak TN-C levels were at high risk of left ventricular (LV) remodelling and poor outcome, suggesting that TN-C could play a significant role in the progression of ventricular remodelling. ...
Tópico(s): Signaling Pathways in Disease
2018 - Oxford University Press | Cardiovascular Research
Ryota Katsumi, Yasutomo Ota, Alto Osada, Takuto Yamaguchi, Takeyoshi Tajiri, Masahiro Kakuda, Satoshi Iwamoto, Hidefumi Akiyama, Yasuhiko Arakawa,
Silicon photonics is a powerful platform for implementing large-scale photonic integrated circuits (PICs) because of its compatibility with mature complementary-metal-oxide-semiconductor (CMOS) technology. Exploiting silicon-based PICs for quantum photonic information processing (or the so-called silicon quantum photonics) provides a promising pathway for large-scale quantum applications. For the development of scalable silicon quantum PICs, a major challenge is integrating on-silicon quantum light ...
Tópico(s): Semiconductor Lasers and Optical Devices
2019 - AIP Publishing | APL Photonics
Margherita Rimini, Mara Persano, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, José Presa, Francesca Salani, Sara Lonardi, Fabio Piscaglia, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Marta Schirripa, Margarida Montes, Caterina Vivaldi, Caterina Soldà, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Valentina Burgio, Mario Scartozzi, Stefano Cascinu, Andrea Casadei‐Gardini,
Tópico(s): Hepatitis B Virus Studies
2023 - Springer Science+Business Media | Journal of Cancer Research and Clinical Oncology
Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Tomomitsu Matono, Hidekatsu Kuroda, Yutaka Yata, Hideko Ohama, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Hiroko Iijima, Masaki Kaibori, Yoichi Hiasa,
The present study focused on Geriatric Nutritional Risk Index (GNRI), which is based on bodyweight and serum albumin, and known as an easy-to-use nutritional assessment tool in clinical settings, to elucidate the prognostic predictive ability of GNRI in patients treated with atezolizumab plus bevacizumab (Atez/Bev) for hepatocellular carcinoma (HCC).A total of 525 HCC patients treated with Atez/Bev, based on their classification of unsuitable status for curative treatments and/or transarterial catheter ...
Tópico(s): Nutrition and Health in Aging
2023 - Wiley | Hepatology Research
Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Tomomitsu Matono, Hidekatsu Kuroda, Yutaka Yata, Hideko Ohama, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Keisuke Yokohama, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Hiroko Iijima, Masaki Kaibori, Yoichi Hiasa,
Introduction: Lack of an established methodology for post-progression systemic treatment following atezolizumab plus bevacizumab (Atez/Bev) administration is an important clinical issue. The present study aimed to elucidate the potential of lenvatinib as a second-line treatment option after Atez/Bev failure. Methods: From 2020 to 2022, 101 patients who received lenvatinib as second-line treatment were enrolled (median 72 years, males 77, Child-Pugh A 82, BCLC-A:B:C:D = 1:35:61:4), while 29 treated with ...
Tópico(s): Hepatitis B Virus Studies
2023 - Karger Publishers | Oncology
Margherita Rimini, Mara Persano, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, José Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Fabio Piscaglia, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Tiziana Pressiani, Margarida Montes, Caterina Vivaldi, Caterina Soldà, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Valentina Burgio, Lorenza Rimassa, Mario Scartozzi, Stefano Cascinu, Andrea Casadei‐Gardini,
Tópico(s): Cholangiocarcinoma and Gallbladder Cancer Studies
2023 - Adis, Springer Healthcare | Targeted Oncology
Mara Persano, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, José Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Francesco Tovoli, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Takashi Niizeki, Margarida Montes, Caterina Vivaldi, Caterina Soldà, Bernardo Stefanini, Atsushi Hiraoka, Takuya Sho, Naoshi Nishida, Christoph Steup, Massimo Iavarone, Giovanni Di Costanzo, Fabio Marra, Emiliano Tamburini, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Marianna Silletta, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Claudia Campani, Elisabeth Amadeo, Federico Rossari, Valentina Burgio, Stefano Cascinu, Mario Scartozzi, Andrea Casadei‐Gardini,
The aim of this retrospective proof-of-concept study was to compare different second-line treatments for patients with hepatocellular carcinoma and progressive disease (PD) after first-line lenvatinib or atezolizumab plus bevacizumab.A total of 1381 patients had PD at first-line therapy. 917 patients received lenvatinib as first-line treatment, and 464 patients atezolizumab plus bevacizumab as first-line.49.6% of PD patients received a second-line therapy without any statistical difference in overall ...
Tópico(s): Cholangiocarcinoma and Gallbladder Cancer Studies
2023 - Elsevier BV | European Journal of Cancer
Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Atsushi Naganuma, Takaaki Tanaka, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Kouji Joko, Hiroko Iijima, Yoichi Hiasa, Masatoshi Kudo,
Although systemic therapy is recommended for patients with multiple intermediate stage unresectable hepatocellular carcinoma (u-HCC) classified as beyond the up-to-7 criteria (UT-7 out/multiple) as a transcatheter arterial chemoembolization (TACE) unsuitable condition, few reports have examined the therapeutic efficacy of atezolizumab plus bevacizumab combination therapy (Atez/Bev) in such cases. This study aimed to elucidate the therapeutic response of Atez/Bev in u-HCC patients classified as UT-7 ...
Tópico(s): Lung Cancer Research Studies
2021 - Wiley | Hepatology Research
Ryota Katsumi, Yasutomo Ota, Takeyoshi Tajiri, Masahiro Kakuda, Satoshi Iwamoto, Hidefumi Akiyama, Yasuhiko Arakawa,
We report a quantum-dot single-photon source (QD SPS) hybrid integrated on a silicon waveguide embedding a photonic crystal mirror, which reflects photons and enables efficient unidirectional output from the waveguide. The silicon waveguide is constituted of a subwavelength grating so as to maintain the high efficiency even under the presence of stacking misalignment accompanied by hybrid integration processes. Experimentally, we assembled the hybrid photonic structure by transfer printing and demonstrated ...
Tópico(s): Neural Networks and Reservoir Computing
2021 - Optica Publishing Group | Optics Express
Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Kouji Joko, Hiroko Iijima, Yoichi Hiasa, Masatoshi Kudo,
Abstract Background Although atezolizumab plus bevacizumab (Atez/bev) treatment has been developed for unresectable hepatocellular carcinoma (u‐HCC), changes in hepatic function during therapy have yet to be reported. Aim This retrospective clinical study aimed to elucidate early responses to Atez/Bev. Methods From September 2020 to April 2021, 171 u‐HCC patients undergoing Atez/Bev treatment were enrolled (BCLC stage A:B:C:D = 5:68:96:2). Of those, 75 had no prior history of systemic treatment. Relative ...
Tópico(s): Cancer Mechanisms and Therapy
2021 - Wiley | Cancer Reports
Takaaki Tanaka, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Kouji Joko, Hiroko Iijima, Masaki Kaibori, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada,
Atezolizumab plus bevacizumab (Atez/Bev) treatment is recommended for unresechepatocellular carcinoma (u-HCC) patients classified as Child-Pugh A (CP-A). This study aimed to elucidate the prognosis of patients treated with Atez/Bev, especially CP-A and -B cases.From September 2020 to March 2022, 457 u-HCC patients treated with Atez/Bev were enrolled (median age 74 years, male:female = 368:89, CP-A:CP-B = 427:30, Child-Pugh score [CPS] 5:6:7:8:9 = 271:156:21:8:1). Therapeutic response was evaluated using RECIST ...
Tópico(s): Hepatitis C virus research
2022 - Wiley | Hepatology Research
Takeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Noritomo Shimada, Kazuhito Kawata, Hisashi Kosaka, Takaaki Tanaka, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Kouji Joko, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Takashi Kumada,
Abstract Aim This study compared the efficacy and safety of atezolizumab and bevacizumab (Atez/Bev) in patients with viral and non‐viral infection in clinical settings. Methods We conducted the retrospective cohort study of 323 BCLC stage B or C hepatocellular carcinoma (HCC) patients with Child‐Pugh class A, and a performance status of 0 or 1 who started Atez/Bev from September 2020 to December 2021 at 22 institutions in Japan. Patients with viral infection was defined as those who were either serum ...
Tópico(s): Hepatitis B Virus Studies
2022 - Wiley | Cancer Medicine
Takeshi Hatanaka, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Takaaki Tanaka, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Kouji Joko, Hiroko Iijima, Yoichi Hiasa, Takashi Kumada,
The present study focused on the association of early bevacizumab (Bev) interruption with the clinical outcome of atezolizumab plus bevacizumab.This retrospective study included 239 patients with advanced hepatocellular carcinoma receiving atezolizumab/Bev from September 2020 to June 2021 at 16 different institutions in Japan. We conducted a 9-week landmark analysis to investigate the association of Bev interruption due to adverse events with the therapeutic efficacy.The median age was 73.0 (68.0- ...
Tópico(s): Colorectal Cancer Treatments and Studies
2022 - Wiley | Hepatology Research
Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Takaaki Tanaka, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Kouji Joko, Hiroko Iijima, Yoichi Hiasa,
Abstract Aim The safety and efficacy of atezolizumab plus bevacizumab (Atez/Bev) in elderly patients with unresectable hepatocellular carcinoma (HCC) have not been sufficiently investigated. Methods A total of 317 patients with HCC treated with Atez/Bev were studied. We compared the survival and frequency of adverse events in elderly versus non‐elderly patients with HCC who were treated with Atez/Bev using an analysis of inverse probability weighting (IPW). Results Univariate analysis adjusted with ...
Tópico(s): Hepatitis C virus research
2022 - Wiley | Cancer Medicine